A rare case of suicidal ideation related to Adalimumab use

Fatima Jafri, Amanda Sammut Department of Medicine, Division of Rheumatology, Harlem Hospital Center, Columbia University Medical Center, New York, NY, USA Introduction: Patients undergoing treatment with an anti-tumor necrosis factor-alpha (TNF-α) agent can, as an adverse event, develop a...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jafri F, Sammut A
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	Adalimumab Lupus Rheumatoid Arthritis Suicidal Ideation Diseases of the musculoskeletal system RC925-935
Acceso en línea:	https://doaj.org/article/b5205c2f01964d77a34a431fccc78aa9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b5205c2f01964d77a34a431fccc78aa9
record_format	dspace
spelling	oai:doaj.org-article:b5205c2f01964d77a34a431fccc78aa92021-12-02T03:54:09ZA rare case of suicidal ideation related to Adalimumab use1179-156Xhttps://doaj.org/article/b5205c2f01964d77a34a431fccc78aa92018-08-01T00:00:00Zhttps://www.dovepress.com/a-rare-case-of-suicidal-ideation-related-to-adalimumab-use-peer-reviewed-article-OARRRhttps://doaj.org/toc/1179-156XFatima Jafri, Amanda Sammut Department of Medicine, Division of Rheumatology, Harlem Hospital Center, Columbia University Medical Center, New York, NY, USA Introduction: Patients undergoing treatment with an anti-tumor necrosis factor-alpha (TNF-α) agent can, as an adverse event, develop anti-TNF-α–induced lupus (ATIL). Neuropsychiatric symptoms such as depression and suicidal ideations are not commonly seen in patients who develop ATIL. We describe a case of a 56-year-old female who developed ATIL and suicidal ideations while on Adalimumab. Case presentation: A 56-year-old female with rheumatoid arthritis (RA) and no known prior history of systemic lupus erythematosus or depression presented with suicidal ideations, joint pains and a malar rash after a recent change in her Adalimumab dose. She was treated for an acute ATIL episode based on her symptoms and serologies which were positive for anti-double-stranded deoxyribonucleic acid antibody. An inpatient psychiatric consultation determined that the patient’s suicidal ideations may be an associated symptom of her current ATIL episode or possibly secondary to her chronic pain and debilitation from her RA. The patient’s Adalimumab was discontinued and she was treated with a course of intravenous glucocorticoid. The patient’s suicidal ideations resolved and her anti-double-stranded deoxyribonucleic acid antibody serologies became negative. She was subsequently started on Abatacept and has achieved remission of her RA with no further suicidal ideations. Discussion: The development of ATIL in patients undergoing treatment with an anti-TNF-α agent is a rare occurrence. The aim of reporting our case is to increase understanding of ATIL by highlighting the occurrence of neuropsychiatric symptoms in a patient who developed ATIL. Keywords: Adalimumab, lupus, rheumatoid arthritis, suicidal ideationJafri FSammut ADove Medical PressarticleAdalimumabLupusRheumatoid ArthritisSuicidal IdeationDiseases of the musculoskeletal systemRC925-935ENOpen Access Rheumatology: Research and Reviews, Vol Volume 10, Pp 113-115 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Adalimumab Lupus Rheumatoid Arthritis Suicidal Ideation Diseases of the musculoskeletal system RC925-935
spellingShingle	Adalimumab Lupus Rheumatoid Arthritis Suicidal Ideation Diseases of the musculoskeletal system RC925-935 Jafri F Sammut A A rare case of suicidal ideation related to Adalimumab use
description	Fatima Jafri, Amanda Sammut Department of Medicine, Division of Rheumatology, Harlem Hospital Center, Columbia University Medical Center, New York, NY, USA Introduction: Patients undergoing treatment with an anti-tumor necrosis factor-alpha (TNF-α) agent can, as an adverse event, develop anti-TNF-α–induced lupus (ATIL). Neuropsychiatric symptoms such as depression and suicidal ideations are not commonly seen in patients who develop ATIL. We describe a case of a 56-year-old female who developed ATIL and suicidal ideations while on Adalimumab. Case presentation: A 56-year-old female with rheumatoid arthritis (RA) and no known prior history of systemic lupus erythematosus or depression presented with suicidal ideations, joint pains and a malar rash after a recent change in her Adalimumab dose. She was treated for an acute ATIL episode based on her symptoms and serologies which were positive for anti-double-stranded deoxyribonucleic acid antibody. An inpatient psychiatric consultation determined that the patient’s suicidal ideations may be an associated symptom of her current ATIL episode or possibly secondary to her chronic pain and debilitation from her RA. The patient’s Adalimumab was discontinued and she was treated with a course of intravenous glucocorticoid. The patient’s suicidal ideations resolved and her anti-double-stranded deoxyribonucleic acid antibody serologies became negative. She was subsequently started on Abatacept and has achieved remission of her RA with no further suicidal ideations. Discussion: The development of ATIL in patients undergoing treatment with an anti-TNF-α agent is a rare occurrence. The aim of reporting our case is to increase understanding of ATIL by highlighting the occurrence of neuropsychiatric symptoms in a patient who developed ATIL. Keywords: Adalimumab, lupus, rheumatoid arthritis, suicidal ideation
format	article
author	Jafri F Sammut A
author_facet	Jafri F Sammut A
author_sort	Jafri F
title	A rare case of suicidal ideation related to Adalimumab use
title_short	A rare case of suicidal ideation related to Adalimumab use
title_full	A rare case of suicidal ideation related to Adalimumab use
title_fullStr	A rare case of suicidal ideation related to Adalimumab use
title_full_unstemmed	A rare case of suicidal ideation related to Adalimumab use
title_sort	rare case of suicidal ideation related to adalimumab use
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/b5205c2f01964d77a34a431fccc78aa9
work_keys_str_mv	AT jafrif ararecaseofsuicidalideationrelatedtoadalimumabuse AT sammuta ararecaseofsuicidalideationrelatedtoadalimumabuse AT jafrif rarecaseofsuicidalideationrelatedtoadalimumabuse AT sammuta rarecaseofsuicidalideationrelatedtoadalimumabuse
_version_	1718401575459749888

A rare case of suicidal ideation related to Adalimumab use

Ejemplares similares